Insider Trading Alert - BMRN, RFMD And KOS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Aug. 4, 2014, 84 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $287.50 to $28,284,584.53.

Highlighted Stocks Traded by Insiders:

Biomarin Pharmaceutical (BMRN) - FREE Research Report

Spiegelman Daniel K, who is EVP, Chief Financial Officer at Biomarin Pharmaceutical, sold 2,229 shares at $61.76 on Aug. 4, 2014. Following this transaction, the EVP, Chief Financial Officer owned 68,676 shares meaning that the stake was reduced by 3.14% with the 2,229-share transaction.

The shares most recently traded at $65.12, up $3.37, or 5.17% since the insider transaction. Historical insider transactions for Biomarin Pharmaceutical go as follows:

  • 4-Week # shares sold: 2,229
  • 12-Week # shares sold: 9,086
  • 24-Week # shares sold: 14,567

The average volume for Biomarin Pharmaceutical has been 1.2 million shares per day over the past 30 days. Biomarin Pharmaceutical has a market cap of $9.1 billion and is part of the health care sector and drugs industry. Shares are down 11.94% year-to-date as of the close of trading on Monday.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Currently, there are 10 analysts who rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMRN - FREE

TheStreet Quant Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Biomarin Pharmaceutical Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half